Stockwinners Market Radar for November 01, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:47 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Inspire Brands and Dunkin' Brands (DNKN), parent company of Dunkin' and Baskin-Robbins, announced that they have entered into a definitive merger agreement under which Inspire will acquire Dunkin' Brands for $106.50 per share in cash in a transaction valued at approximately $11.3B including the assumption of Dunkin' Brands' debt. The transaction is expected to close by the end of 2020. 2. The Centers for Disease Control and Prevention said that about a dozen pharmacy chains will partner with the federal government to administer COVID-19 vaccines, Bloomberg's Angelica LaVito reported. CVS Health (CVS), Walgreens Boots Alliance (WBA) and Walmart (WMT) are among those that have already enrolled to receive vaccines directly from the CDC, the author noted. The companies represent about 35,000 stores, and the CDC anticipates more chains will sign up, LaVito added. 3. Videogames have been one of the stock market's star attractions in 2020, mostly powered by COVID-19 quarantines and the coming release of new game consoles from Sony (SNE) and Microsoft (MSFT), Max Cherney wrote in this week's edition of Barron's. Another long-running trend related trend predated the pandemic, however, and that is mobile gaming, with an estimated two billion people now playing videogames on mobile devices, the author noted. Videogame makers all benefit from the broad participation, but there are limited pure-play stocks on the theme. The largest in the U.S. is Zynga (ZNGA), the publication pointed out, adding that shares could have significant upside in the year to come. 4. The Justice Department's antitrust case against Google (GOOGL) bears a striking resemblance to the U.S. government lawsuit against Microsoft 20 years ago, and Google is desperate not to make the same mistakes as its forerunner, Bloomberg's Gerrit De Vynck wrote. The 1998 complaint, and Microsoft's aggressive and scattered defense, is credited with slowing the software giant down and letting upstarts -- including Google -- gain a foothold. Even though Microsoft avoided being broken up, the years of public scrutiny and court drama were a debilitating distraction, the author noted. Internal memos from CEO Sundar Pichai and top lawyer Kent Walker sent to employees after the lawsuit dropped implore workers to keep their heads down and keep working, the publication added. "It's important not to get distracted by this process, including not speculating on legal issues internally or externally," Walker wrote in an Oct. 20 memo obtained by Bloomberg. 5. Parker-Hannifin (PH), Littelfuse (LFUS), TE Connectivity (TEL), AT&T (T) and Anthem (ANTM) saw positive mentions in this week's edition of Barron's.

14:16 EST Eli Lilly, Incyte showcase new data for Baricitinib in moderate to several AD - Eli Lilly (LLY) and Incyte (INCY) announced new data for baricitinib that reinforces "Lilly's commitment to developing medicines for the treatment of dermatologic diseases such as moderate to severe atopic dermatitis," the company said in a statement. At this year's virtual EADV meeting, data from BREEZE-AD3, a Phase 3 study evaluating the long-term efficacy and safety of baricitinib in adult patients with moderate to severe AD will be shared. In the study, responders as assessed by the validated Investigator Global Assessment score of "clear or almost clear" skin and partial responders from one of the 16-week originating studies entered and continued treatment with baricitinib 2-mg or 4-mg once daily for an additional 52 weeks. At the start of BREEZE-AD3, 45.7% of responders and partial responders on 4-mg of baricitinib had a vIGA-AD score of 0 or 1, while 40% had a vIGA-AD score of 0 or 1 after 68 weeks of continuous therapy. Similarly, at the start of BREEZE-AD3 46.3% of responders and partial responders on 2-mg of baricitinib had a vIGA-AD score of 0 or 1, while 50% had a vIGA-AD score of 0 or 1 after 68 weeks of continuous therapy. These results indicate that baricitinib 4-mg and 2-mg dose groups were able to maintain clear or almost clear skin response rates through the 68-week treatment period. The safety profile in this study was consistent with the known safety findings of baricitinib in previous 16-week, placebo-controlled AD studies. Earlier this week, Lilly announced baricitinib received approval in the European Union for the treatment of adult patients with moderate to severe AD who are candidates for systemic therapy.

13:25 EST Dunkin' Brands buyout expected to close by end of 2020 - Inspire Brands and Dunkin' Brands Group said, "The closing of the tender offer will be subject to certain conditions, including the tender of shares representing at least a majority of the total number of Dunkin' Brands' outstanding shares, the expiration or termination of the antitrust waiting period, and other customary conditions. Following the successful completion of the tender offer, Inspire will acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price. The transaction is expected to close by the end of 2020."